1 / 33

Treatment Strategies for MPNSTs

Outline. Neurofibromatosis type 1 (NF1)MPNST Epidemiology/symptoms/risk factorsGrowth control pathwaysPreclinical ModelsCurrent treatments for MPNSTOther molecular targetsFuture Directions. NF1: Neurofibromatosis type 1. Familial tumor predisposition syndromeGermline mutations in the NF1 tum

toni
Download Presentation

Treatment Strategies for MPNSTs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. Treatment Strategies for MPNSTs Angela C. Hirbe Hematology Oncology Grand Rounds 5/4/2012 No Financial Disclosures

    2. Outline Neurofibromatosis type 1 (NF1) MPNST Epidemiology/symptoms/risk factors Growth control pathways Preclinical Models Current treatments for MPNST Other molecular targets Future Directions

    3. NF1: Neurofibromatosis type 1 Familial tumor predisposition syndrome Germline mutations in the NF1 tumor suppressor gene: 17q11.2 >85% cutaneous neurofibromas 33% plexiform neurofibromas 3-5% develop MPNSTs -benign and malignant tumors of the peripheral and central nervous system-benign and malignant tumors of the peripheral and central nervous system

    4. NF1: Neurofibromatosis type 1

More Related